Heparin Market - Historic Data (2019-2024), Global Trends 2025, Growth Forecasts 2037
Heparin Market in 2025 is assessed at USD 11.33 billion. The global market size was worth over USD 10.94 billion in 2024 and is expected to see a CAGR exceeding 4.4%, reaching over USD 19.15 billion by 2037. North America is set to capture the leading share, led by rising chronic kidney disease cases and higher healthcare expenditure.
The market growth is primarily driven by higher instances of cancer among the population. For instance, in 2040, the new cancer case count is anticipated to be nearly 28 million and the death toll is likely to reach around 16 million. Furthermore, rising prevalence of coronary artery disease and venous thromboembolism is fueling the market revenue.
Additionally, rising cases of accidents owing to vehicle crashes will propel the global heparin market growth. As per the data of the World Health Organization, road accident is the most common cause of death of children and adults aged 5 to 29 and about 1.3 million people every year die in road accident globally. Moreover, blood clotting during surgeries owing to several conditions will boost the market size.
Heparin Sector: Growth Drivers and Challenges
Growth Drivers
-
Growing Pressure of Chronic Diseases on the World - Chronic diseases/Non-communicable diseases are currently the major cause of death among adults in almost all countries. This growing burden of chronic diseases is anticipated to boost the heparin market. As per the National Library of Medicine, every 3 in 5 deaths are attributed to a chronic disease such as cardiovascular disease, lung problem, diabetes, and others.
-
Rising Cases of Thromboembolism - In the United States, around 900,000 people are affected by pulmonary embolism or deep vein thrombosis. Moreover, up to 100,000 deaths are caused by venous thromboembolism globally.
-
Increase in Number of Cancer Patients - According to the World Health Organization, in 2020, around 2 million new cases of lung cancer and nearly 2.26 million of breast cancer were reported. Moreover, 10 million people died because of cancer.
-
Increased Cases of Injury and Deaths by Road Accidents - Fatal and non-fatal road accidents impose a burden of approximately 8 trillion dollars on the world’s economy and globally every day, around 3700 people die in a road accident.
-
Higher Instances of Renal Failure- For instance, globally, around 850 million people have acquired some kind of kidney problem.
Challenges
-
Side Effects of Heparin in Some Patients - Side effects associated with heparin such as, chest pain, irregular heartbeats, skin discoloration, irregular bleeding, shortness of breath, and others are likely to hamper the growth of the heparin market.
-
The dearth of Raw Material Required for the Heparin Formulation
- Higher Cost of Certain Types of Heparin
Heparin Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
4.4% |
|
Base Year Market Size (2024) |
USD 10.94 billion |
|
Forecast Year Market Size (2037) |
USD 19.15 billion |
|
Regional Scope |
|
Heparin Segmentation
Application (Deep Vein Thrombosis, Heart Attacks, Stroke, Atrial Fibrillation)
The heart attacks segment is poised to garner highest heparin market share by the end of 2037. This can be attributed to rising prevalence of heart-related disorders across the globe. According to the World Health Organization, in 2019, around 18 million people die due to cardiovascular diseases and the rise in cardiovascular problems is driving the growth of the segment.
Route of Administration (Intravenous Infusion, Subcutaneous Injection)
The subcutaneous injection segment is set to dominate largest market share, owing to growing demand for home healthcare services, low hospitalized associated costs, and a few more properties like convenience in administration. The higher tolerance rate of patients for subcutaneous heparin performs as a benefit for the segment expansion.
Our in-depth analysis of the global market includes the following segments:
|
By Product Type |
|
|
By Route of Administration |
|
|
By Application |
|
|
By End-User |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Heparin Industry - Regional Synopsis
North American Market Forecast
The North American heparin market is anticipated to account for majority share by the end of 2037. The market growth is attributed to higher number of people developing chronic kidney diseases, followed by surging healthcare expenditure. According to the Centers for Disease Control and Prevention, in 2021, 15% of adults in the United States have chronic kidney disease which is nearly 37 million people in the country. Moreover, rising instances of road accidents will propel the market growth. As of January 2022, about 1 million road accidents took place in the United States.
APAC Market Statistics
The heparin market in Asia Pacific is estimated to witness significant growth during the forecast period. The expansion in venous thromboembolism and cardiovascular diseases, increasing geriatric population, rising chronic disease in a large population, growing healthcare expenditure, and initiatives undertaken by the government of the region are the primary factors driving the growth of the market.
Companies Dominating the Heparin Landscape
- Aspen Holdings
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Opocrin S.p.A.
- LEO Pharma Inc.
- Baxter
- Dr. Reddy’s Laboratories Ltd.
- Pfizer Inc.
- B. Braun Medical Inc.
- Bioiberica S.A.U.
- Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
- Fresenius Kabi Canada
Recent Developments
-
Amcor Group GmbH has launched its latest OmniPack PET bottles to meet the requirements for e-commerce-ready packaging. Amcor has designed a family of stock PET bottles that help co-packers to meet demanding requirements for e-commerce-ready packaging.
-
ALPLA Group along with Voslaur has entered into a partnership to develop a new PET bottle for the Austrian market that will reduce the carbon footprint by 30% and reduces bottle weight by almost 90% in comparison to reusable substitute made up of glass.
Author Credits:
- Report ID: 3402
- Published Date: Apr 18, 2025
- Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Heparin Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
